Sugi Predict

Sugi Predict / Compounds / SCHEMBL396186

SCHEMBL396186

SCHEMBL396186

NCCSC(C[N+](=O)[O-])c1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 2/20 0.54
▸ SLC6A3 Q01959 2/20 0.54
▸ MAPT P10636 6/20 0.43
▸ NPSR1 Q6W5P4 3/20 0.43
▸ TDP1 Q9NUW8 3/20 0.43
▸ HPGD P15428 3/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ NTSR1 P30989 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ ALDH1A1 P00352 5/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ SERPINH1 P50454 2/20 0.42
▸ HSP90AA1 P07900 1/20 0.42
▸ AGTR1 P30556 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.40
▸ APOBEC3G Q9HC16 1/20 0.40
▸ CNR1 P21554 1/20 0.40
▸ GABBR2 O75899 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7614254 0.78 PDPK1 (0.53) SLC6A4SLC6A3MAPTNPSR1TDP1
Nitralamine SCHEMBL29387852 0.77 NPSR1 (0.52) SLC6A4SLC6A3MAPTNPSR1TDP1
Nitralamine SCHEMBL396184 0.75 NPSR1 (0.54) SLC6A4SLC6A3MAPTNPSR1TDP1
SCHEMBL17491642 0.74 MAPT (0.75) MAPTNPSR1TDP1HPGDMEN1
SCHEMBL341755 0.72 GABBR2 (0.56) SLC6A4SLC6A3MAPTNPSR1HPGD
SCHEMBL15389394 0.71 ALDH1A1 (0.48) MAPTNPSR1HPGDMEN1KMT2A
SCHEMBL16011789 0.71 SLC6A4 (1.00) SLC6A4SLC6A3MEN1KMT2AGABBR2
SCHEMBL7255012 0.71 MAPT (0.56) MAPTNPSR1TDP1HPGDMEN1
SCHEMBL7258556 0.71 SERPINH1 (0.56) MAPTNPSR1TDP1HPGDMEN1
SCHEMBL7258520 0.70 MAPT (0.54) MAPTNPSR1TDP1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 — — US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 — — US claimed
WO-2006081327-A2 SMALL MOLECULES THAT REDUCE FUNGAL GROWTH UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) 2006-08-03 — — WO claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 — — US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 — — US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 — — US claimed
EP-1578434-A2 METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS Point Therapeutics, Inc. (US) 2005-09-28 — — EP claimed
US-20040131628-A1 Nucleic acids for the treatment of disorders associated with microorganisms BRATZLER ROBERT L (US) 2004-07-08 — — US claimed
US-20040077601-A1 Methods and compositions relating to isoleucine boroproline compounds POINT THERAPEUTICS, INC. 2004-04-22 — — US claimed
WO-2004004658-A2 METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS POINT THERAPEUTICS, INC. (US) 2004-01-15 — — WO claimed
EP-4706683-A2 CHEWABLE FORMULATIONS Elanco Tiergesundheit AG (CH) 2026-03-11 — — EP disclosed
US-20260034059-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES AQUESTIVE THERAPEUTICS, INC. (US) 2026-02-05 — — US disclosed
US-20250346906-A1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE ALNYLAM PHARMACEUTICALS INC (US) 2025-11-13 — — US disclosed
US-12465564-B2 Oral and nasal compositions and methods of treatment AQUESTIVE THERAPEUTICS, INC. (US) 2025-11-11 — — US disclosed
US-20250339367-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES AQUESTIVE THERAPEUTICS, INC. (US) 2025-11-06 — — US disclosed
WO-1999036570-A2 TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE PERICOR SCIENCE INC (US) 1999-07-22 — — WO disclosed
WO-1999030690-A1 ORAL DELIVERY FORMULATION AXIA THERAPEUTICS, INC. (US) 1999-06-24 — — WO disclosed
EP-0909183-A2 DHA-PHARMACEUTICAL AGENT CONJUGATES Neuromedica, Inc. (US) 1999-04-21 — — EP disclosed
US-5795909-A ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS NEUROMEDICA, INC. (US) 1998-08-18 — — US disclosed
WO-1997044063-A2 DHA-PHARMACEUTICAL AGENT CONJUGATES NEUROMEDICA, INC. (US) 1997-11-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346906-A1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE CD274, PDCD1LG2, PDCD4 SLC6A4 3799/4885SLC6A3 3124/4885MAPT 3942/4885
US-20260034059-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES SORD, SLC6A13, CACNA1A SLC6A4 120/4885SLC6A3 291/4885MAPT 97/4885
US-20040077601-A1 Methods and compositions relating to isoleucine boroproline compounds BCAT1, BCAT2, APOB SLC6A4 517/4885SLC6A3 734/4885MAPT 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.